Plain-English translation of NCT06915025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a new medication called IMNN-001, given directly into the abdomen, combined with standard chemotherapy to treat advanced ovarian, fallopian tube, or peritoneal cancer. Half of the participants will receive IMNN-001 plus chemotherapy, while the other half will receive chemotherapy alone. The goal is to see if adding this medication helps patients live longer and live better after their treatment.
Standard chemotherapy alone doesn't work well enough for all patients with advanced ovarian cancer, and some patients' cancers come back. This medication is designed to boost the immune system's ability to fight cancer cells, and researchers hope that combining it with chemotherapy will improve survival and outcomes.
You likely qualify if…
You likely don't qualify if…
You would receive chemotherapy infusions every 3 weeks for 6 total cycles (3 before surgery, 3 after). If you're in the treatment group, you would also receive the new medication injected into your abdomen on specific days during your chemotherapy cycles — 17 treatments total over the course of several months. You would have surgery between your first and second sets of chemotherapy. After chemotherapy ends, you would receive standard maintenance therapy and be monitored regularly by the research team, with an independent safety committee overseeing the trial to protect all participants.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States